Covalent EGFR Inhibitors: Binding Mechanisms, Synthetic Approaches, and Clinical Profiles

Being overexpressed in several types of cancer, the epidermal growth factor receptor (EGFR) is considered one of the key therapeutic targets in oncology. Although many first‐generation EGFR inhibitors had been FDA approved for the treatment of certain types of cancer, patients soon developed resista...

Ausführliche Beschreibung